[Viva] Fwd: De-simplifying single-tablet regimens for HIV treatment

[Tami Starlight]

Interesting.

-- 
Hiy Hiy/Thank you/Merci
*Tami M. Starlight*
Unceded Coast Salish Territory
Vancouver, Canada
tamistarlight at gmail.com

https://www.facebook.com/TheAntiOppressionNetworkUncededCoastSalish

https://www.facebook.com/TheAntiONetwork

<https://www.facebook.com/TheAntiONetwork>
http://theantioppressionnetwork.wordpress.com



A Calgary HIV clinic offered patients a cheaper drug regimen with more than
one pill
[image: CATIE News]

View this e-mail in your browser
<https://mailchi.mp/91fe1448232c/de-simplifying-single-tablet-regimens-for-hiv-treatment?e=0f7b6f861c>
De-simplifying single-tablet regimens for HIV treatment

   - A Calgary HIV clinic offered patients a cheaper drug regimen with more
   than one pill
   - Over half of participants chose to switch and achieved high rates of
   viral suppression
   - The clinic reduced drug costs 16% in 2017, and projected $3 million in
   savings in 2018

<https://catie.us16.list-manage.com/track/click?u=89abcbccf295c7b8d9a92cf09&id=1a8900383e&e=0f7b6f861c>
Share
<https://catie.us16.list-manage.com/track/click?u=89abcbccf295c7b8d9a92cf09&id=d5f5448d8b&e=0f7b6f861c>
<https://catie.us16.list-manage.com/track/click?u=89abcbccf295c7b8d9a92cf09&id=0fd3b77b11&e=0f7b6f861c>
Tweet
<https://catie.us16.list-manage.com/track/click?u=89abcbccf295c7b8d9a92cf09&id=6776232083&e=0f7b6f861c>
<http://us16.forward-to-friend.com/forward?u=89abcbccf295c7b8d9a92cf09&id=3e1ad0ccd5&e=0f7b6f861c>
Forward
<http://us16.forward-to-friend.com/forward?u=89abcbccf295c7b8d9a92cf09&id=3e1ad0ccd5&e=0f7b6f861c>

In the late 1980s, early formulations of HIV drugs required taking pills
frequently, in one case, every four hours. In the mid-to-late 1990s, when
potent combination HIV treatment (ART) became available, pill-taking became
less frequent, usually three times daily. However, HIV-positive people
often had to swallow a fistful of pills at each dosing interval.

About a decade ago, pharmaceutical companies began to put entire regimens
in one pill (single-tablet regimens) that could be taken once daily. The
marketing departments of these companies touted the “simplification” that
such single-tablet regimens could bring to patients. Today, single-tablet
regimens are widely used as first-line and even second-line treatment, as
they simplify dosing and cut down the number of pills a patient needs to
take. The latest versions of single-tablet regimens are also generally very
well tolerated.
Growth, money and drug costs

In the aftermath of the financial-economic crisis in 2008, the rate of
economic growth in Canada and other high-income countries generally fell
and governments received less revenue. One policy response to the
financial-economic crisis that many governments have chosen is the
imposition of austerity programs. As a result, government spending on
healthcare and other needed services is constrained compared to earlier
decades when economic growth rates were more robust and inequality was less
prominent. One important service that many governments in high-income
countries provide is subsidized access to medicines for catastrophic
conditions such as cancer, hepatitis C virus and HIV infection. As a
result, the cost of drugs for these and other conditions tends to concern
policy makers, hospitals, clinics and departments and ministries of health.

There are several steps that have been taken around the world to help
reduce the burden of HIV drug prices on payers, such as the following:

   - Low- and middle-income countries generally buy generic formulations.
   - In some countries, particularly in southern Europe, some clinics
   privilege the use of functional mono- or dual-therapy in people who have a
   suppressed viral load with combinations such as darunavir (Prezista) +
   low-dose ritonavir or atazanavir (Reyataz) + low-dose ritonavir with or
   without the addition of 3TC (lamivudine).
   - Canada’s provinces and territories engage in bargaining with
   pharmaceutical companies about the price of new drugs for HIV and many
   other conditions. Despite this bargaining, the resulting prices still eat a
   large amount of money from provincial and territorial healthcare budgets.
   As a result, some HIV clinics still strive to further reduce drug costs.

De-simplification

The Southern Alberta Clinic (SAC) in Calgary provides care and treatment
for the majority of HIV-positive people in that region. Researchers at SAC
have modelled the impact of what they call “de-simplification,” which they
define as “switching a single-tablet formulation to two or more tablets of
the same drugs with one or more drugs being generic…”

After surveying doctors and participants at SAC about de-simplifying HIV
treatment, researchers at SAC began what they called a “soft rollout
program of voluntary de-simplification.” That is, participants were offered
the option of de-simplification. The researchers focused on one particular
single-tablet regimen—Triumeq, which contains the following drugs:
dolutegravir + abacavir + 3TC. They chose Triumeq because it was widely
used in their clinic and is relatively easy to de-simplify, as generic
abacavir + 3TC have been available in Canada for several years.

Researchers offered participants who were either on Triumeq or initiating
ART with Triumeq the option of one of the following regimens:

   - continue taking Triumeq (taken as one pill once daily)
   - de-simplification – one pill containing dolutegravir (Tivicay) and one
   pill containing generic abacavir + 3TC; both pills taken once daily

The rollout began in November 2016 and data were collected up to April 1,
2018.

Participants were told of the price difference between the two regimens and
were allowed to freely choose one of the regimens. Furthermore, if a
participant later decided to change their mind, they were allowed to return
to Triumeq (if their initial regimen was Triumeq).

Importantly, the researchers stated that the patient as well as their
pharmacist and doctor all had to agree that the switch to or initiation
with a de-simplified regimen was appropriate for the patient. The
researchers stated: “No extra resources, incentives or reimbursement to the
participants, physicians, pharmacists, before or after the program were
offered.”
Results

Researchers approached different groups of participants about
de-simplification, as follows:

   - 321 participants who were already taking Triumeq. Of these people, 55%
   (177 people) agreed to de-simplify their regimen.
   - 67 participants who were initiating ART with Triumeq. Of these people,
   63% chose a de-simplified regimen.
   - 41 participants who were talking multi-tablet regimens (usually based
   on protease inhibitors). All of these participants chose to switch to a
   de-simplified regimen.

Who switched?

According to the researchers, participants who chose to de-simplify their
regimens were “more likely to be male, older and white and were gay or
bisexual and lived longer with HIV” than participants who rejected
de-simplification.
Why did some people not de-simplify?

A total of 144 people chose to not de-simplify their regimen; the most
common reason (86%) for not de-simplifying was a preference for a
single-tablet regimen. According to the researchers, participants who
declined to de-simplify “were predominantly female, younger, people of
colour, had fewer years of education, more likely to be heterosexual”
compared to people who did switch their regimen.
Virological control

During the study, 3.4% of participants who were taking Triumeq developed
viral loads greater than 500 copies/mL. Furthermore, two participants who
initiated ART with Triumeq never achieved viral suppression. In contrast,
among people who either switched to or initiated ART with a de-simplified
regimen, only 1.2% had a viral load greater than 500 copies/mL three months
after they began taking a de-simplified regimen.
Money saved

In 2017, the researchers found that moving to a de-simplified regimen
resulted in a 16% decrease in drug costs for SAC. The clinic projects
further savings in 2018 as the de-simplification process continues and
expects to save $3 million.
Bear in mind

According to the research team, participants who decided to remain on or
initiate treatment with Triumeq “valued the convenience of single-tablet
regimens.”

Achieving and maintaining an undetectable viral load is the main goal of
HIV care and treatment today. The researchers were pleased that the vast
majority of participants taking a de-simplified regimen achieved and/or
maintained a suppressed viral load.
Drug development in the private sector

Pharmaceutical companies, like all corporations, are by their nature profit
driven. They will expand into therapeutic areas where their profit is high
and avoid investment in therapeutic areas where profit is likely low. An
example of this strategy is that more pharmaceutical companies are
investing in developing and marketing novel anti-cancer drugs. The price
for some of the latest cancer drugs can range from about US $100,000 to
about $500,000 per person per year. Another example is the area of
antibiotics. Most antibiotics that are commonly used now are generic and
there has not been major large-scale private investment in the discovery
and development of many new antibiotics as there has been with the
development of new drugs for cancer. Any new antibiotic developed would
have to compete against cheaper generic formulations. Also, antibiotics are
usually used only for a short time, and doctors may reserve the use of new
antibiotics only for very ill patients. All of these factors affect
for-profit companies, which see them as disincentives for investment in
antibiotic drug development.

In the area of HIV treatment, the main companies are Gilead Sciences, Merck
and ViiV. They are still conducting research on new drugs and new
formulations (long-acting) for the treatment of HIV and expect new drugs to
be approved over the next several years. However, there will likely be
pressure on these (and other companies) to keep prices for new drugs in a
range that is sustainable for departments and ministries of health.

*Resources*

Will de-simplification of HIV treatment become common in high-income
countries?
<https://catie.us16.list-manage.com/track/click?u=89abcbccf295c7b8d9a92cf09&id=30008c686f&e=0f7b6f861c>
– CATIE News

*—Sean R. Hosein*

REFERENCES:

   1. Krentz HB, Campbell S, Lahl M, et al. De-simplifying single-tablet
   antiretroviral treatments: uptake, risks and cost savings. HIV Medicine.
   2019; *in press*.
   2. Martin EG, Schackman BR. Treating and preventing HIV with generic
   drugs – Barriers in the United States. *New England Journal of Medicine*.
   2018 Jan 25;378(4):316-319.
   3. Tooze A. How a decade of financial crises changed the world. 1st ed.
   New York: Viking; c2018.
   4. Godman B, Bucsics A, Vella Bonanno P, et al. Barrier for access to
   new medicines: Searching for the balance between rising costs and limited
   budgets.  *Frontiers in Public Health*. 2018 Dec 5;6:328
   5. Gupta R, Shah ND, Ross JS. Generic drugs in the United States:
   Policies to address Pricing and Competition.  *Clinical Pharmacology and
   Therapeutics*. 2019; *in press*.
   6. Pataky R, Tran DA, Coronado A, et al. Cancer drug expenditure in
   British Columbia and Saskatchewan: a trend analysis. *CMAJ Open*. 2018
   Jul 27;6(3):E292-E299.
   7. Rosenberg M, Chai G, Mehta S, et al. Trends and economic drivers for
   United States naloxone pricing, January 2006 to February 2017. *Addictive
   Behaviours*. 2018 Nov;86:86-89.
   8. Sehested TSG, Bjerre J, Ku S, et al. Cost-effectiveness of
   Canakinumab for prevention of recurrent cardiovascular events. *JAMA
   Cardiology*. 2019; *in press*.
   9. Tay-Teo K, Ilbawi A, Hill SR. Comparison of sales income and research
   and development costs for FDA-approved cancer drugs sold by originator drug
   companies. *JAMA Network Open*. 2019 Jan 4;2(1):e186875.
   10. Engelhard EA, Smit C, Vervoort SC, et al. Patients' willingness to
   take multiple-tablet antiretroviral therapy regimens for treatment
of HIV. *Drugs
   – Real World Outcomes*. 2016 May 2;3(2):223-230.
   11. Foreman C, Gazzard B, Johnson M, et al. Maintaining cost-effective
   access to antiretroviral drug therapy through a collaborative approach to
   drug procurement, consensus treatment guidelines and regular audit: the
   experience of London HIV commissioners and providers. *Sexually
   Transmitted Infections*. 2012 Mar;88(2):112-115.
   12. Rex JH, Outterson K. Antibiotic reimbursement in a model delinked
   from sales: a benchmark-based worldwide approach. *Lancet Infectious
   Diseases*. 2016 Apr;16(4):500-5.
   13. Savage P, Mahmoud S, Patel Y, et al. Cancer drugs: An international
   comparison of postlicensing price inflation. *Journal of Oncology
   Practice*. 2017 Jun;13(6):e538-e542.
   14. Harbarth S, Theuretzbacher U, Hackett J, et al. Antibiotic research
   and development: business as usual? *Journal of Antimicrobial
   Chemotherapy*. 2015;70(6):1604-7.
   15. Bettiol E, Wetherington JD, Schmitt N, et al. Challenges and
   solutions for clinical development of new antibacterial agents: results of
   a survey among pharmaceutical industry professionals. *Antimicrobial
   Agents and Chemotherapy.* 2015 Jul;59(7):3695-9

*Subscribe to the CATIE Quarterly*
<https://catie.us16.list-manage.com/track/click?u=89abcbccf295c7b8d9a92cf09&id=3c820edd3b&e=0f7b6f861c>
Looking for news, opinions and resources you can use in your work?
Subscribe to the CATIE Quarterly. New issue focused on harm reduction
coming out on February 7. Sign up here
<https://catie.us16.list-manage.com/track/click?u=89abcbccf295c7b8d9a92cf09&id=e09fb44b02&e=0f7b6f861c>
.
<https://catie.us16.list-manage.com/track/click?u=89abcbccf295c7b8d9a92cf09&id=81ae54f924&e=0f7b6f861c>
<https://catie.us16.list-manage.com/track/click?u=89abcbccf295c7b8d9a92cf09&id=a7d8c7b16e&e=0f7b6f861c>
<https://catie.us16.list-manage.com/track/click?u=89abcbccf295c7b8d9a92cf09&id=4d06f8ae60&e=0f7b6f861c>
<https://catie.us16.list-manage.com/track/click?u=89abcbccf295c7b8d9a92cf09&id=0c68934171&e=0f7b6f861c>
<https://catie.us16.list-manage.com/track/click?u=89abcbccf295c7b8d9a92cf09&id=abd01a7078&e=0f7b6f861c>
<https://catie.us16.list-manage.com/track/click?u=89abcbccf295c7b8d9a92cf09&id=86e2ee2735&e=0f7b6f861c>

*Our mailing address is:*
CATIE 555 Richmond St. West Suite 505 Toronto, On M5V 3B1 Canada
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.resist.ca/pipermail/viva/attachments/20190205/3edd7b67/attachment-0001.html>